Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica

Page 1 of about 3 results

ea0041ep589 | Endocrine tumours and neoplasia | ECE2016

Proposal of a two-step dynamic prognostic stratification for stage IV sporadic pancreatic neuroendocrine tumors

Marotta Vincenzo , Walter Thomas , Do Cao Christine , Tafuto Salvatore , Montesarchio Vincenzo , Arfi-Rouche Julia , Valette Pierre Jean , Lombard-Bohas Catherine , Leteurtre Emmanuelle , Borget Isabelle , Scoazec Jean Yves , Ducreux Michel , Faggiano Antongiulio , Colao Annamaria , Baudin Eric

Purpose: To validate a prognostic stratification system of overall survival (OS) in stage IV pancreatic neuroendocrine tumors (pNETs) naïve of therapy by analyzing 1) prognostic parameters at the time of stage IV diagnosis; 2) the role of spontaneous tumor slope.Patients and Methods: Multicenter retrospective study including consecutive patients diagnosed with stage IV pNET from January 1997 to March 2014. Inclusion criteria were: 1. pNET w...
0 shares

ea0099oc7.2 | Oral Communications 7: Endocrine-related Cancer | ECE2024

[177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study

Ferone Diego , Halperin Daniel , Myrehaug Sten , Herrmann Ken , Pavel Marianne , Kunz Pamela , Chasen Beth , Capdevila Jaume , Tafuto Salvatore , Oh Do-Youn , Yoo Changhoon , Falk Stephen , Halfdanarson Thorvardur R , Folitar Ilya , Zhang Yufen , Santoro Paola , Aimone Paola , de Herder Wouter W , Singh Simron

Background: There is no universally accepted first-line (1L) therapy for higher grade, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The Phase 3 NETTER-2 study (NCT03972488) evaluated [177 Lu]Lu-DOTA-TATE (hereafter177 Lu-DOTATATE) as 1L treatment in patients with grade (G)2 and G3 advanced GEP-NETs. This is the first trial to assess 1L radioligand therapy (RLT) in any solid tumor.Methods: Eligible pat...
0 shares

ea0098t5 | Trials In Progress | NANETS2023

Phase 3 LEVEL trial of 177Lu-edotreotide vs everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin (GETNE-T2217)

Capdevila Jaume , Fazio Nicola , Alvarez Rosa , Ansquer Catherine , Baldari Sergio , Baudin Eric , Benavent Marta , Benini Lavinia , Beron Amandine , Berruti Alfredo , Cingarlini Sara , del Olmo-Garcia Maribel , Deshayes Emmanuel , Garcia-Alvarez Alejandro , Garcia-Carbonero Rocio , Haissaguerre Magalie , Hernando Jorge , Anido Herranz Urbano , Jimenez-Fonseca Paula , Lepage Come , Llana Belen , Molina-Cerrillo Javier , Panzuto Francesco , Pubul Virginia , Sansovini Maddalena , Tafuto Salvatore , Taieb David , Teule Alex , Versari Annibale , Villacampa Guillermo , Walter Thomas

Background: Everolimus is the only approved drug for patients with advanced bronchopulmonary neuroendocrine tumors (NET), and there is an urgent unmet need for alternative treatments. Retrospective data for peptide receptor radionuclide therapy (PRRT) have demonstrated promising activity in somatostatin receptor (SST)-positive lung NET. This study aims to investigate the clinical efficacy, safety, and patient-reported outcomes when 177Lu-edotreotide is used to treat...
2 shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more